Amica Mature Lifestyles (TSX:ACC)
Over the past week there were three insiders making notable buys into Amica Mature Lifestyles.
Director Charles van der Lee bought a total of 683 shares at $8.95 per share. This transaction cost him a total of $6,112.85. Since his buy the price per share has increased about 0.45%. van der Lee now holds on to at least 58,921 shares of company stock.
James MacCallum added 10,000 shares to his stake over the past week. The corporate executive purchased these shares at an average price of $8.93 per share for a total transaction amount of $89,300. Since his buy, the price per share has increased about 0.67%.
Colin Halliwell made the largest transaction, adding 50,000 shares to his stake. Halliwell bought these shares at an average price of $8.93 per share. This cost Halliwell a total of $446,500. Since this buy the price per share has increased 0.67%. Halliwell holds on to at least 285,750 shares.
The company has seen an increase in insider buying as the price sits around a high.
The company is engaged in the design, development, marketing, management and ownership of luxury seniors’ residences. The Company earns revenues from the ownership and operation of senior residences, management fees, design and marketing fees during the development, construction and lease-up of the seniors’ residences.
Amica Mature Lifestyles’ historical revenue and net income:
Amica Mature Lifestyles has a market cap of $275.906 million. Its shares are currently trading at around $8.97 with a P/S ratio of 2.80, a P/E ratio of 4.80 and a P/B ratio of 1.75. The company currently holds a dividend yield of 4.68%
Canadian Tire Corp. (TSX:CTC.A)
Over the past week Dean Charles McCann made several transactions adding 5,200 shares to his stake. He bought these shares in the price range of $91.52 to $92.10 per share. Since his purchases, the price per share has increased approximately 0.52%.
The company has seen an increase in insider buying coming from McCann as the price has hit a 5-year high.
Canadian Tire is comprised of two main business operations that offer a range of retail goods and services including general merchandise, clothing, sporting goods, petroleum and financial services. The Company's two segments are Retail and Financial Services Retail.
Canadian Tire’s historical revenue and net income:
The analysis on the company reports that the company’s revenue has slowed over the past year, that its price is nearing a 5-year high, its dividend yield is near a 5-year low and its asset growth is currently faster than its revenue.
The company has reported several big things happening over the past week. First off the Canadian Tire REIT filed its preliminary prospectus for initial public offering of trust units. And it was also announced that the Maple Leaf Sports & Entertainment would enter in to a long-term partnership with the Canadian Tire Family of Companies. You can read more about this here.
The Peter Lynch Chart suggests that the company is currently undervalued:
Canadian Tire has a market cap of $7.14 billion. Its shares are currently trading at around $92.66 with a P/E ratio of 14.47, a P/S ratio of 0.66 and a P/B ratio of 1.76. The company had an annual average earnings growth of 5% over the past ten years.
GuruFocus rated Canadian Tire the business predictability rank of 4-star.
Valeant Pharmaceuticals (TSX:VRX)
Over the past week corporate executive Laizer Kornwasser made a notable buy of his company’s stock. The Chairman and Executive VP added 1,000 shares to his stake at an average price of $99.0182 per share. This cost the insider a total of $99,018.20. Since his buy the price per share has increased 10%. Kornwasser now holds on to a total of 6,500 shares of company stock.
Also at the end of August Norma Provencio made a notable buy of 4,500 shares. She bought these shares at an average price of $100.711. She now holds on to 114,468 shares of company stock.
Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Valeant Pharmaceuticals’ historical revenue and net income:
The company recently announced that it has continued via the federal jurisdiction of Canada to the Province of British Columbia since the resolution was passed by shareholders of the company’s annual meeting held at the end of May.
The analysis on Valeant reports that the company’s price is nearing a 10-year high, the company has issued $6.4 billion of debt over the past three years and its P/E and P/S ratio are trading at record highs.
Valeant Pharmaceuticals International has a market cap of $36.26 billion. Its shares are currently trading at around $108.92 with a P/E ratio of 714.29, a P/S ratio of 8.08 and a P/B ratio of 5.81. The company had an annual average earnings growth of 4.2% over the past ten years.
Check out the Canadian Insider Trading page for more Canadian insider buys and sells.
If you don’t have the GuruFocus Global Membership, try a free 7-day trial here.